These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30793642)

  • 1. Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.
    Tanaka Y; Takeuchi T; Okada M; Ishii T; Nakajima H; Kawai S; Nagashima T; Hayashi N; Wang L; Tummala R
    Mod Rheumatol; 2020 Jan; 30(1):101-108. PubMed ID: 30793642
    [No Abstract]   [Full Text] [Related]  

  • 2. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R; Khamashta M; Merrill JT; Werth VP; Kalunian K; Brohawn P; Illei GG; Drappa J; Wang L; Yoo S;
    Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.
    Takeuchi T; Tanaka Y; Matsumura R; Saito K; Yoshimura M; Amano K; Atsumi T; Suematsu E; Hayashi N; Wang L; Tummala R
    Mod Rheumatol; 2020 Jan; 30(1):93-100. PubMed ID: 30791804
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study.
    Chatham WW; Furie R; Saxena A; Brohawn P; Schwetje E; Abreu G; Tummala R
    Arthritis Rheumatol; 2021 May; 73(5):816-825. PubMed ID: 33225631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.
    Tanaka Y; Tummala R
    Mod Rheumatol; 2021 Jan; 31(1):1-12. PubMed ID: 32814461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
    Morand EF; Furie R; Tanaka Y; Bruce IN; Askanase AD; Richez C; Bae SC; Brohawn PZ; Pineda L; Berglind A; Tummala R;
    N Engl J Med; 2020 Jan; 382(3):211-221. PubMed ID: 31851795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
    Bruce IN; Nami A; Schwetje E; Pierson ME; Rouse T; Chia YL; Kuruvilla D; Abreu G; Tummala R; Lindholm C
    Lancet Rheumatol; 2021 Feb; 3(2):e101-e110. PubMed ID: 38279367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials.
    Tummala R; Abreu G; Pineda L; Michaels MA; Kalyani RN; Furie RA; Morand EF
    Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33597205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.
    Kalunian KC; Furie R; Morand EF; Bruce IN; Manzi S; Tanaka Y; Winthrop K; Hupka I; Zhang LJ; Werther S; Abreu G; Hultquist M; Tummala R; Lindholm C; Al-Mossawi H
    Arthritis Rheumatol; 2023 Feb; 75(2):253-265. PubMed ID: 36369793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations.
    Anderson E; Furie R
    Immunotherapy; 2020 Apr; 12(5):275-286. PubMed ID: 32237942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure-response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus.
    Chia YL; Santiago L; Wang B; Kuruvilla D; Wang S; Tummala R; Roskos L
    Rheumatology (Oxford); 2021 Dec; 60(12):5854-5862. PubMed ID: 33629110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.
    Petri M; Wallace DJ; Spindler A; Chindalore V; Kalunian K; Mysler E; Neuwelt CM; Robbie G; White WI; Higgs BW; Yao Y; Wang L; Ethgen D; Greth W
    Arthritis Rheum; 2013 Apr; 65(4):1011-21. PubMed ID: 23400715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis.
    Tanaka Y; Atsumi T; Okada M; Miyamura T; Ishii T; Nishiyama S; Matsumura R; Kawakami A; Hayashi N; Abreu G; Yavuz S; Lindholm C; Al-Mossawi H; Takeuchi T
    Mod Rheumatol; 2024 Jul; 34(4):720-731. PubMed ID: 37706527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date.
    Felten R; Scher F; Sagez F; Chasset F; Arnaud L
    Drug Des Devel Ther; 2019; 13():1535-1543. PubMed ID: 31190735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review.
    Liu Z; Cheng R; Liu Y
    Front Immunol; 2022; 13():996662. PubMed ID: 36211347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus.
    Almquist J; Kuruvilla D; Mai T; Tummala R; White WI; Tang W; Roskos L; Chia YL
    J Clin Pharmacol; 2022 Sep; 62(9):1106-1120. PubMed ID: 35383948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis.
    Tanaka Y; Atsumi T; Okada M; Miyamura T; Ishii T; Nishiyama S; Matsumura R; Hayashi N; Abreu G; Tummala R; Morand EF; Takeuchi T
    Mod Rheumatol; 2023 Jan; 33(1):134-144. PubMed ID: 35134970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus.
    Chia YL; Tummala R; Mai TH; Rouse T; Streicher K; White WI; Morand EF; Furie RA
    J Clin Pharmacol; 2022 Sep; 62(9):1094-1105. PubMed ID: 35352835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of anifrolumab for use in adults with systemic lupus erythematosus.
    Ahmed AA; Osman N; Furie R
    Expert Rev Clin Immunol; 2022 Nov; 18(11):1095-1106. PubMed ID: 36083692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.
    Baker T; Sharifian H; Newcombe PJ; Gavin PG; Lazarus MN; Ramaswamy M; White WI; Ferrari N; Muthas D; Tummala R; Morand EF; Furie RA; Vital EM; Chamberlain C; Platt A; Al-Mossawi H; Brohawn PZ; Csomor E
    Ann Rheum Dis; 2024 Jul; 83(8):1018-1027. PubMed ID: 38569851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.